Back to Sorafenib

Sorafenib

Showing 2 study arms with grade ≥3 adverse event data (treatment-related and RT-related). Click a column header to sort.

Note on patient counts: some articles reported only percentages rather than absolute numbers. Where this occurred, the number of patients — including those with grade ≥3 adverse events — was derived by applying the reported percentage to the total arm size, which may produce a non-integer value. These figures have been rounded to the nearest integer for display.

1st Author⇅	Year⇅	Study Type⇅	Title⇅	DOI⇅	clinical trial number⇅	number of patients⇅	median/mean age⇅	tumor type⇅	treatment setting⇅	drug group⇅	drug name⇅	if other, please specify⇅	number of SBRT courses⇅	intracranial / extracranial⇅	treated site⇅	If other treated site, please specify⇅	median/mean total RT dose [Gy]⇅	minimum total RT dose [Gy]⇅	maximum total RT dose [Gy]⇅	median/mean number of fractions⇅	minimum number of fractions⇅	maximum number of fractions⇅	median/mean dose per fraction [Gy]⇅	minimum dose per fraction [Gy]⇅	maximum dose per fraction [Gy]⇅	toxicity type⇅	patients with acute G>=3 toxicity⇅	patients with late G>=3 toxicity⇅	patients with G>=3 toxicity, timing unspecified⇅	G>=3 AEs⇅	patients with G>=3 AEs⇅	details on G>=3 toxicity⇅	details on G>=3 toxicity in RT field⇅
Dawson et al.	2025	Prospective	Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial.	10.1001/jamaoncol.2024.5403	NCT01730937	83	66	HCC	primary	Multi-target TKI	Sorafenib	—	83	extra-cranial	liver	—	Missing	20	50	Missing	2	5	Missing	6	10	Treatment-rel.	—	—	39	any G3: 35 AEs, any G4: 3 AEs, any G5: 1 AE	any G3: 35 pts, any G4: 3 pts, any G5: 1 pt	any G3: nausea, vomiting, diarrhea, duodenal perforation, duodenal ulcer, ascites, gastric/upper GI hemorrhage, lower GI hemorrhage, alanine aminotransferase increased, aspartatte aminotrasnferase increased, blood bilirubin increased, platelet count decreased, skin, hypertension, any G4: hepatic failure, hepatic hemorrhage, platelet count decreased, any G5: lung infection	—
Goody et al.	2017	Prospective	Phase I trial of radiation therapy and sorafenib in unresectable liver metastases	10.1016/j.radonc.2017.01.018	NCT00892424	18	62	Breast cancer, Colorectal cancer, Melanoma, other	primary, metastatic	Multi-target TKI	Sorafenib	—	18	extra-cranial	liver	—	Missing	30	60	6	6	6	Missing	5	10	Treatment-rel.	10	—	—	acute G3: 8, acute G4: 1	acute G3: unknown pts, acute G4: 1 pt	acute G3: generalized skin toxicity, hand foot syndrome, musculoskeletal, abdominal pain, hyponatremia, hypophosphatemia, acute G4: abdominal pain	acute G3: abdominal pain